All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”
EN
ČeštinaEnglish

Filters

57 (0,102s) •

Project

The role of FLT3 gene internal tandem duplications in deregulated signaling networks and development of acute myeloid leukemia. (NS9651)

Acute myeloid leukemia (AML) is a malignant clonal disorder of hematopoiesis. Molecular markers have been identified allowing to stratify AML patients into prognostic (FLT3/ITD) represent an unfavorable prognostic marker in AML<...

FD - Onkologie a hematologie

  • 2008 - 2011
    • •
  • 5 818 tis. Kč
    • •
  • 5 788 tis. Kč
    • •
  • MZ
Project

Casein kinase 1 alpha (CK1a) inhibition as a novel therapeutic approach for AML (NW25-03-00225)

Acute myeloid leukemia (AML) is a hematologic malignancy with an unfavorable strategies, AML still remains a fatal disease. Recently, inhibition of the CK1? enzyme has been found to be a viable strategy for the treatment of AML<...

Oncology

  • 2025 - 2028
    • •
  • 14 136 tis. Kč
    • •
  • 14 136 tis. Kč
    • •
  • MZ
Project

Molecular cytogenetic analysis of complex chromosomal aberrations in bone marrow cells of patients with myelodysplastic syndrome (MDS) and/or acute myeloid leukemia (AML) and AND its contribution (NR9227)

Molecular cytogenetic analysis of complex chromosomal aberrations in patients with MDS and AML. Identification of chromosomes and/or chromosomal regions involved in complex karyotypes. Evaluation of the impact of complex rearrangements on pr...

EB - Genetika a molekulární biologie

  • 2007 - 2009
    • •
  • 3 054 tis. Kč
    • •
  • 2 953 tis. Kč
    • •
  • MZ
Project

Development of resistance mechanisms to FLT3 inhibitors; role of bone marrow microenvironment (NU23-03-00562)

Acute myeloid leukemia (AML) is a hematological malignancy with a low treatment receptor, which is constitutively activated in about a third of patients with AML due into therapy has reduced the risk of relapse and prolonged the sur...

Oncology

  • 2023 - 2026
    • •
  • 11 380 tis. Kč
    • •
  • 11 380 tis. Kč
    • •
  • MZ
Project

New molecular markers for monitoring of residual disease in acute myeloid leukemia patients (NS10632)

New molecular markers for monitoring minimal residual disease in patients with acute myeloid leukemia (AML). Quantitative determination of gene expression, mutation, and methylation in samples from AML patients. Evaluation of correl...

FD - Onkologie a hematologie

  • 2009 - 2011
    • •
  • 7 576 tis. Kč
    • •
  • 7 576 tis. Kč
    • •
  • MZ
Project

Molecular characteristic of childhood acute myeloid leukemia and myelodysplastic syndrome (OC09051)

working goals of EuGESMA) on the ed scientific problems concerning childhood AML and stratification of childhood AML and MDS. We will test the potential of polychromatic flow in the diagnosis and follow-up of childhood AML...

FD - Onkologie a hematologie

  • 2009 - 2012
    • •
  • 3 234 tis. Kč
    • •
  • 2 450 tis. Kč
    • •
  • MŠMT
Project

C/EBPg in normal hematopoiesis and acute myeloid leukemia identification of the molecular mechanisms involved in cellular transformation (LK21307)

Acute myeloid leukemia (AML) is a malignant transformation process, with exception of C/EBPg, were linked to block of differentiation and pathogenesis of AML is upregulated in a specific subtype of AML samples characterized...

FD - Onkologie a hematologie

  • 2013 - 2015
    • •
  • 12 816 tis. Kč
    • •
  • 12 816 tis. Kč
    • •
  • MŠMT
Project

The optimalization of expensive examination and treatment procedures aimed at the augmentation of treatment effectiveness and mortality reduction in AML patients based on clinical and high (NR9481)

I. Evaluation of known and newly detected prognostic factors in AML using hematologic, cytogenetic and molecular genetic methods, follow up the response to various cells transplantations. II. Keeping continuity in reporting AML pati...

FD - Onkologie a hematologie

  • 2007 - 2010
    • •
  • 4 723 tis. Kč
    • •
  • 4 511 tis. Kč
    • •
  • MZ
Project

The role of RUNX1, EVI1 and CEBPA genes in the pathogenesis of leukemias and pre-leukemias (NR9045)

. Mutations in genes for transcription factor RUNX1 in AML and MDS patients and transcription factor CEBPA in AML patients will be analysed. The elevated level of transcription factor EVI1 mRNA is unfavorable prognostic marker for p...

FD - Onkologie a hematologie

  • 2006 - 2008
    • •
  • 6 857 tis. Kč
    • •
  • 6 492 tis. Kč
    • •
  • MZ
Project

New kinase inhibitors to treat acute myeloid leukemia (NV15-28951A)

Treatment of acute myeloid leukemia (AML) is challenging and some AML subtypes have very poor prognosis. AML therapeutics that inhibit the oncogenic FLT3 receptor in AML cell lines with FLT3 mutations: they abrogat...

FD - Onkologie a hematologie

  • 2015 - 2018
    • •
  • 10 476 tis. Kč
    • •
  • 10 476 tis. Kč
    • •
  • MZ
  • 1 - 10 out of 57